10-Q quarterly report · filed Nov 2, 2026

Boston Scientific (BSX) Q3 2026 10-Q Quarterly Report

Short answer

Boston Scientific (BSX) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $5.1B (up 1.5% year over year) with net income of $583M.

Q3 2026 key financials · XBRL

Revenue
$5.1B
+1.5% YoY · −5.6% QoQ
Net income
$583M
−22.8% YoY · −35.7% QoQ
Operating margin
16.1%
Gross margin
66.7%
EPS (diluted)
$0.41
−19.6% YoY · −32.8% QoQ

Source: XBRL data from the Boston Scientific (BSX) Q3 2026 10-Q on SEC EDGAR. USD.

Boston Scientific Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $5.138B, up 1.5% YoY from $5.065B
  • Gross margin 66.7% vs 69.9% YoY; adjusted net income $1.063B vs $1.124B
  • Best segment Cardiovascular, $3.406B, up 1.9%; worst Urology, down 3.2%
  • Operating cash flow $2.870B for nine months vs $3.170B; $2.000B share repurchase
  • Headwinds: cybersecurity disruption, Electrophysiology competition, WATCHMAN™ market deceleration, tariff uncertainty

Risk Factors

  • Cybersecurity incident risk: August 26, 2026 incident could disrupt operations and financial results
  • Penumbra acquisition regulatory risk: FTC issued a Second Request on March 16, 2026
  • Spinal cord stimulator litigation risk: MDL consolidated federal product-liability cases on June 5, 2026
  • Supply-chain restructuring risk: 2026 plan transfers production lines through 2029
  • Commercial paper liquidity risk: $1.029 billion outstanding, reducing available capacity to $1.721 billion

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Boston Scientific quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.